Evaluation of complex chronic disease monitoring & management system on the glucose control and patients’ satisfaction in the type 2 diabetes with primary clinic outpatient care

At the three-month follow-up, the participants in the intervention group showed increased reduction in HbA1c (-0.63 ± 0.82 vs. -0.27 ± 0.71 %, p < 0.0001) and fasting plasma glucose (-18.86 ± 63.35 vs. -2.33 ± 53.67 mg/dL, p = 0.0125) levels compared to those in the control group. At 3 months of baseline, the HbA1c 7% reach rate was 6.67% (10 patients) in the intervention group and 6.19% (6 patients) in the control group and there was no statistically significant difference between the two groups (p-value = 0.8807). The HbA1c 6.5% reach rate was 32.67% (49 patients) in the test group and 23.71% (23 patients) in the control group. There was no statistically significant difference between the two groups (p-value = 0.1304). A significantly increased reduction in diastolic blood pressure (BP), a tendency for reduced systolic BP, and elevated high-density lipoprotein cholesterol level were also observed in the intervention group. In the subgroup analysis, the effect on glycemic control was more significant among patients with good compliance to self-monitoring blood glucose, younger age (under 60 years), and poor baseline control (HbA1c = 8%). In addition, increased treatment satisfaction and medication adherence were observed in the intervention group. 18 patients (12.00%) in the test group and 8 patients (8.25%) in the control group showed 26 cases of adverse events. All adverse events were not causally related to the test device. Cerebral infarction-related deaths occurred in one (1) subject in the control group with significant adverse events, but the causal relationship with the testing device was not clearly related and there were no drug-related actions taken.